Ann: Investor Webinar Notification - SPL Business Update, page-2

Investor Webinar Notification –
Starpharma Business Update
Melbourne, Australia; 20 May 2024: Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased
to announce that it will host an investor webinar on Wednesday, 22 May 2024, to provide
shareholders with a business update.
Following CEO Cheryl Maley’s commencement in January, Starpharma's CEO, Board of
Directors, and management team have conducted a strategic review of the Company. During
the webinar, the CEO, Cheryl Maley, will provide an update on Starpharma’s priorities moving
forward and provide an opportunity to address questions from investors. Starpharma’s CFO
and Company Secretary, Justin Cahill, VP of Business Development, Dr Tony Eglezos, and VP
of Development and Regulatory Affairs, Dr Jeremy Paull, will also join the call.
Shareholders can submit questions during the webinar, but in the best interest of time, they are
encouraged to send them to [email protected] before the webinar.
Webinar details
Date: Wednesday, 22 May 2024
Time: 11:00 AM AEST (Melbourne/Sydney) / 09:00 AM AWST (Perth)
Link to register: https://us02web.zoom.us/webinar/register/WN_7OPr15-
jSu680T4DlNxsIg#/registration
Starpharma will share a copy of the presentation deck before Wednesday’s webinar via the
ASX market announcements platform. After the webinar, a recording will be available on
Starpharma’s website, www.starpharma.com.
2
About Starpharma
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications. As
an innovative Australian biopharmaceutical company, Starpharma is focused on developing and commercialising novel therapeutic
products that address significant global healthcare needs. Starpharma boasts a strong portfolio of products, partnerships, and
intellectual property.
Starpharma’s innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically
manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of
branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.
Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing
pharmaceuticals. Starpharma’s portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced
Product (‘DEP®
’ drug delivery technology, and marketed products, including VIRALEZE™ and VivaGel® BV, which utilise
SPL7013, a proprietary dendrimer with antimicrobial properties.
Starpharma’s DEP® drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to reduce
drug-related toxicities through controlled and specified drug delivery.
In addition to Starpharma’s internal DEP® programs, Starpharma has multiple DEP® partnerships with international
biopharmaceutical companies, including AstraZeneca (oncology), MSD (Antibody-Drug Conjugates), Chase Sun (anti-infectives),
and other world-leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma’s DEP® platform,
partnered DEP® programs have the potential to generate significant future milestones and royalties.
Starpharma’s topical nasal spray, Viraleze™, is registered in more than 35 countries*, including Europe, the UK, and Asia.
Starpharma’s novel non-antibiotic vaginal gel, VivaGel® BV, for the treatment of bacterial vaginosis (BV) and prevention of recurrent
BV, is registered in more than 50 countries, including in the UK, Europe, Southeast Asia, South Africa, Australia and New Zealand.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on Linked